<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128998</url>
  </required_header>
  <id_info>
    <org_study_id>NICR-CT2008-01</org_study_id>
    <nct_id>NCT01128998</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus S-1 in Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        1. To define the recommended dose for phase II study of S-1 combined with sorafenib&#xD;
&#xD;
        2. To evaluate the dose-limiting toxicities of the combination therapy&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To characterize the pharmacokinetics (PK) of sorafenib and S-1 in the combination&#xD;
           therapy&#xD;
&#xD;
        2. To investigate the impact of genetic polymorphisms of metabolic genes on the PK of&#xD;
           sorafenib and S-1, respectively, as well as on the toxicity profile of the combination.&#xD;
&#xD;
        3. To determine the changes of biomarkers between pre- and post-treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD/RD</measure>
    <time_frame>First two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting Toxicity</measure>
    <time_frame>First two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Name: Sorafenib&#xD;
Dosage form: 200 mg / Tablet&#xD;
Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1</description>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Name:S-1&#xD;
Dosage form: 20 mg or 25 mg / Capsule&#xD;
Dosing schedule: 20-40 mg/m2 bid,po, 14 days on &amp; 7 days off</description>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven metastatic or locally advanced malignant solid&#xD;
             tumors, which are refractory to current standard systemic treatment.&#xD;
&#xD;
          -  Have measurable lesion.&#xD;
&#xD;
          -  20-75 y/o.&#xD;
&#xD;
          -  ECOG performance score no more than 2.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  Adequate hematopoietic, hepatic and renal functions.&#xD;
&#xD;
               1. Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
               2. Absolute neutrophil count &gt; 1,500/mm3&#xD;
&#xD;
               3. Platelet count 100,000/ mm3&#xD;
&#xD;
               4. Total bilirubin &lt; 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               5. ALT and AST &lt; 2.5 x ULN&#xD;
&#xD;
               6. Serum creatinine &lt; 1.0 x ULN&#xD;
&#xD;
          -  Recovery from prior therapy that given &gt; 4 weeks before enrolment.&#xD;
&#xD;
          -  No pregnancy and breast-feeding.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiovascular disorders.&#xD;
&#xD;
          -  Pulmonary fibrosis or interstitial pneumonia.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Major anti-cancer treatment within 4 weeks of study entry.&#xD;
&#xD;
          -  Exposure to the current investigational agent before.&#xD;
&#xD;
          -  Known or suspected allergy to the current investigational agent.&#xD;
&#xD;
          -  Unable to swallow oral medications.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions interfering with the&#xD;
             patient's participation or evaluation of the study results.&#xD;
&#xD;
          -  Any condition that is unstable or could jeopardize the safety of the patient and their&#xD;
             compliance in the study.&#xD;
&#xD;
          -  Symptoms of bowel obstruction, malnutrition, splenomegaly.&#xD;
&#xD;
          -  Receiving active anti-coagulant therapy.&#xD;
&#xD;
          -  Patients with concurrent CYP 2A6 and/or CYP 3A4 or 3A5 inducers or inhibitors; a&#xD;
             minimal of 2 weeks wash-out period required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Cancer Research, National Health Research Institution, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>S1</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>RD</keyword>
  <keyword>MTD</keyword>
  <keyword>DLT</keyword>
  <keyword>PK</keyword>
  <keyword>PG</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

